Блог
Последни новини, научни статии и полезна информация за молекулярната онкологична диагностика и персонализираната терапия.
The polygenic, omnigenic and stratagenic models of complex disease risk
This study discusses polygenic, omnigenic and stratagenic models developed to explain multigenic disease risk. It proposes means to test their validity, which has implications for research, drug development and precision medicine.
Optineurin binding to the novel interacting partner Junction plakoglobin prevents muscle atrophy in mice
Skeletal muscle atrophy is a debilitating condition that accompanies a number of diseases, but there are few known therapeutic targets to reverse it. This study identifies Optineurin as a regulator of muscle homeostasis, showing that it binds to JUP and activ…
Inside AstraZeneca’s long-term strategy in lung cancer
Decades-long research has yielded a strong and growing franchise built around drugs for a genetic form of lung cancer.
Identification of Targetable EGFR Mutations in Ovarian Cancer
Ovarian cancer driven by an oncogenic <i>EGFR</i> mutation is a rare occurrence, yet it is an actionable molecular target with EGFR-directed inhibitors. This un...
Beyond the Scalpel: EGFR Mutation Predicts Intraoperative Blood Loss and Transfusion Needs During Lung Cancer-derived Spinal Metastasis Surgery
This study identified EGFR mutation as a novel molecular predictor of hemorrhagic risk in LCSM surgery, independent of systemic therapy status. The quantifiable...
Oncology Companion Diagnostic Market Projected to Reach US$ 12.84 Billion by 2035, Supported by Expanding Genomic Testing Adoption Says Astute Analytica
Regulatory deregulation and liquid biopsy adoption pushing the rapid growth of the oncology companion diagnostic market. In addition to this, strategic pharmaceutical partnerships and widespread next-generation sequencing integration are solidifying precision…
Страница 11 от 13 • Общо 75 статии